Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Amgen logo
AmgenAMGN
20.6×-6.3×
Incyte logo
IncyteINCY
3.3×+0.1×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
4.6×+2.9×
Arcus Biosciences logo
Arcus BiosciencesRCUS
5.2×+3.6×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s price / book?
Arcutis Biotherapeutics, Inc. (ARQT) reported price / book of 15.4× in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s price / book changed year-over-year?
Arcutis Biotherapeutics, Inc.'s price / book increased by 18.5% year-over-year, from 13× to 15.4×.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s price / book?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s price / book has grown at a 29.1% compound annual growth rate (CAGR), from 5.2× to 18.8×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.